Please login to the form below

Not currently logged in
Email:
Password:

Caldan Therapeutics appoints CEO

Dr Mark Payton joins the Universities of Glasgow and Southern Denmark spin-out

Caldan Therapeutics Dr Mark PaytonEdinburgh, UK-based Caldan Therapeutics has appointed Dr Mark Payton as chief executive officer.

Dr Payton joins the metabolic disease specialist - a spin-out company from the Universities of Glasgow and Southern Denmark - from MAPBiotech, where he has served as chief executive officer since 2014.

Prior to this, Dr Payton has been chief executive officer of both Atopix Therapeutics and Oxagen, both based in Oxfordshire, UK, and brings further industry experience from GlaxoSmithKline and Biogen.

He co-founded autoimmune disease-focused Orca Pharmaceuticals in 2012, and currently also serves as a senior advisor to The Harrington Project for Discovery and Development.

Dr Liz Roper, partner at Epidarex Capital, which backs Caldan Therapeutics, said: “We are delighted to welcome Mark on board to lead Caldan Therapeutics moving forward.

“Continuing to build a strong management team with experienced and talented executives is crucial to building on the science of Professors Milligan and Ulven to deliver new drugs for metabolic diseases.”

8th March 2017

From: Sales

Share

Tags

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Research Partnership

We are the largest independent healthcare market research and consulting agencies in the world. Trusted partner to the global pharmaceutical...

Latest intelligence

Unlocking the potential of science and technology in the UK
Greater collaboration is vital in post-Brexit UK, says Alderley Park leader...
NHS regional footprints
What to expect from 2019...
Not another weight-loss ad
Christmas is over and the gyms are packed, it’s a never-ending tale. But why do we do it to ourselves every year?...

Infographics